Radium-223 dichloride (Side Effects) Common side effects include: Nausea Diarrhea Vomiting Peripheral edema (swelling of the legs or hands) Decreased blood cell counts (anemia, thrombocytopenia, leukopenia)
Category: Oncology
Radium-223 dichloride (Benefits) Targeted Treatment: Xofigo’s ability to target bone metastases specifically reduces tumor burden in the bone, which can help alleviate pain and other symptoms associated with bone metastases. Survival Benefit: Clinical trials have shown that Xofigo can extend overall survival and improve the quality of life for patients with mCRPC.
Radium-223 dichloride (Administration) Dosage: Xofigo is administered by intravenous injection. The standard dosing regimen is 50 kBq (1.35 microcurie) per kg body weight, given at 4-week intervals for six injections. Preparation and Handling: Due to its radioactive nature, Xofigo must be handled with care by trained healthcare professionals using appropriate safety protocols to avoid unnecessary […]
Radium-223 dichloride (Indications) Metastatic Castration-Resistant Prostate Cancer (mCRPC): Xofigo is indicated for the treatment of patients with mCRPC that has spread to bones but not to other organs. It is used in patients who are symptomatic and have received other therapies such as hormonal treatment or chemotherapy.
Radium-223 dichloride (Mechanism of Action) Radium-223 is an alpha emitter, meaning it releases alpha particles, which are a type of high-energy radiation. These alpha particles cause double-strand DNA breaks in nearby cells, leading to targeted killing of cancer cells in the bone while minimizing damage to surrounding healthy tissue. The short range of alpha particles […]
Categories
Carmustine (Contraindications)
Carmustine (Contraindications): Carmustine is contraindicated in patients with: Severe bone marrow suppression Active infection History of allergic reactions to carmustine